Tubulis

Develops next-generation antibody-drug conjugates for cancer, led by its TUB-040 candidate, and was acquired by Gilead in 2026.

View on the globe

$401MEquity raised in 2025–20262025 $401M · 2026 — · 1 equity round
$401MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 1 round from 15 Oct 2025 to 15 Oct 2025, $401M equity disclosed. Earlier rounds exist but are not sourced.15 Oct 2025: Series C, $401M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedest. 2019Q2Q3Q42026Q2Q3Equity round15 Oct 2025 · Series C · $401M · led by VenrockSeries C · $401M
Funding history: 1 round from 15 Oct 2025 to 15 Oct 2025, $401M equity disclosed. Earlier rounds exist but are not sourced.15 Oct 2025: Series C, $401M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yetearlier rounds not sourced’19Q2Q3Q42026Q2Q3Equity round15 Oct 2025 · Series C · $401M · led by Venrock$401M

Funding history 1 round · 3 sources

Earlier rounds not yet sourced. Tubulis was founded in 2019 and raised before 15 Oct 2025; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Series C
    Amount$401MEUR 344M
    Post-money—
    ✓ Confirmed
    Lead
    Venrock
    Also
    Wellington Management, Ascenta Capital, Nextech Invest, EQT, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, High-Tech Gründerfonds, Fidelity, Janus Henderson Investors, Blackstone
    Note
    Initial close EUR 308M (US $361M) on 2025-10-15; second and final closing on 2025-10-30 brought the total to EUR 344M (US $401M), recorded here as one round. Lead: Venrock Healthcare Capital Partners. Also participating: Fund+, OCCIDENT, Seventure Partners. Gilead completed its acquisition of Tubulis on 2026-05-21 ($3.15B upfront plus up to $1.85B in milestones). Earlier rounds are not sourced.
    Sources
  2. Earlier rounds not yet sourced

Investors 13

  • Venrock1
  • Andera Partners
  • Ascenta Capital
  • Bayern Kapital
  • Blackstone
  • Deep Track Capital
  • EQT
  • Fidelity
  • Frazier Life Sciences
  • High-Tech Gründerfonds
  • Janus Henderson Investors
  • Nextech Invest
  • Wellington Management

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Also in the Munich hub see on the globe

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Tubulis and its logo are trademarks of their owners, used here for identification only.